龙启生物制药

Longqi Biopharmaceutical is a China-based biotechnology company focused on the research and development of innovative biopharmaceuticals, particularly in the field of oncology. The company leverages its expertise in antibody engineering and small molecule drug discovery to develop therapies targeting critical pathways in cancer progression, such as PD-1 and VEGF. Headquartered in Suzhou's BioBAY, Longqi Biopharmaceutical aims to address unmet medical needs through the creation of high-quality, affordable biologics and targeted therapies. Their current pipeline is primarily in the discovery and pre-clinical stages, focusing on next-generation immunotherapy and anti-angiogenic agents.